Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting

Sponsor
Boston Sight (Other)
Overall Status
Completed
CT.gov ID
NCT04649177
Collaborator
EYEdeal scanning, LTC (Other)
10
1
1
15.2
0.7

Study Details

Study Description

Brief Summary

EYEdeal Scanning Technology enables rapid measurement of corneal and scleral topography. By accurately measuring the ocular surface with this imaging technology, the current iterative fitting method required to fit PROSE (prosthetic replacement of the ocular surface ecosystem) devices could be replaced and/or strengthened with a more rapid, automated fitting sequence. This could considerably reduce the time needed per visit, the number of visits, and the number of devices needed to be manufactured to reach the endpoint. Additionally, the scanning technology may afford the opportunity to successfully fit some pathology that were previously treatment failures. The automated technology may as well reduce the intensive clinician training time needed to fit PROSE devices, therefore increasing the availability and access to patients.

The goal of this research is to evaluate the reliability and efficacy of this automated technology for fitting PROSE devices. Data from real-time measurement of the human eye ocular surface topography will be used to fabricate a prosthetic lens. The fit of the PROSE device will be evaluated, as well as the subjective comfort of the fit.

Condition or Disease Intervention/Treatment Phase
  • Device: Ocular surface optical coherence tomography
N/A

Detailed Description

Inclusion and Exclusion Criteria

The participant will be eligible to participate if the following criteria apply:
  1. Written Informed Consent has been obtained prior to any study-related procedures

  2. Male or female, 18 years of age and older prior to the initial visit

  3. Established wearer of PROSE in the study eye with an optimized fit in the opinion of the clinician

  4. No medical need for a PROSE retreatment or replacement lens at the time of enrollment in the study eye, in the opinion of the clinician

  5. Initial PROSE fitting was initiated and completed at BostonSight, Needham

  6. Current PROSE device does not have channels or fenestrations

  7. Currently wears a PROSE device in the study eye primarily for an irregular ocular surface /irregular cornea (including but not limited to Keratoconus, Pellucid Marginal Degeneration, Ectasia, Post-Penetrating Keratoplasty, Corneal Scar, Trauma) AND/OR ocular surface disease

  8. Has the ability to NOT wear the current PROSE device in the study eye for 3 days prior to scan and 3 days prior to first fitting appointment in the opinion of the investigator and subject

  9. In the opinion of the investigator, the subject has the ability to follow study instructions

  10. In the opinion of the investigator, the subject has the ability to complete all study procedures and visits

The participant would NOT be eligible to participate if at least one of the following criteria is met:

  1. Is currently participating in any other type of eye-related clinical or research study

  2. Is pregnant or nursing as reported by the subject

  3. Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study

  4. Has had previous ocular surgery within the past 12 weeks

  5. Intolerance to PROSE wear

  6. Inability to maintain stable fixation and exposure for ocular surface imaging

  7. Corneal touch by the posterior surface of the device in current PROSE device

  8. Allergy to sodium fluorescein

  9. Patient is an employee of BostonSight

  10. Subject is currently incarcerated.

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting
Actual Study Start Date :
Dec 15, 2020
Actual Primary Completion Date :
Mar 23, 2022
Actual Study Completion Date :
Mar 23, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: study group

There is only one study group in this study. All subjects will receive the OCT scanning and PROSE lens fitting.

Device: Ocular surface optical coherence tomography
EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices

Outcome Measures

Primary Outcome Measures

  1. Central Corneal Clearance [45 minutes post lens application]

    microns

  2. Lens decentration [45 minutes post lens application]

    microns

  3. Lens comfort [45 minutes post lens application]

    0 to 10 grading

  4. Lens centration [45 minutes post lens application]

    centered/decentered

  5. Scleral landing zone [45 minutes post lens application]

    aligned/impingement/edge lift

Secondary Outcome Measures

  1. Lens rotation [45 minutes post lens application]

    degrees

  2. Acceptable fitting lens [45 minutes post lens application]

    yes/no

  3. Lens movement [45 minutes]

    none/minimal/excessive

  4. Lens limbal clearance [45 minutes post lens application]

    inadequate/adequate/excessive

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Written Informed Consent has been obtained prior to any study-related procedures

  2. Male or female, 18 years of age and older prior to the initial visit

  3. Established wearer of PROSE in the study eye with an optimized fit in the opinion of the clinician

  4. No medical need for a PROSE retreatment or replacement lens at the time of enrollment in the study eye, in the opinion of the clinician

  5. Initial PROSE fitting was initiated and completed at BostonSight, Needham

  6. Current PROSE device does not have channels or fenestrations

  7. Currently wears a PROSE device in the study eye primarily for an irregular ocular surface /irregular cornea (including but not limited to Keratoconus, Pellucid Marginal Degeneration, Ectasia, Post-Penetrating Keratoplasty, Corneal Scar, Trauma) AND/OR ocular surface disease

  8. Has the ability to NOT wear the current PROSE device in the study eye for 3 days prior to scan and 3 days prior to first fitting appointment in the opinion of the investigator and subject

  9. In the opinion of the investigator, the subject has the ability to follow study instructions

  10. In the opinion of the investigator, the subject has the ability to complete all study procedures and visits

Exclusion Criteria:
  1. Is currently participating in any other type of eye-related clinical or research study

  2. Is pregnant or nursing as reported by the subject

  3. Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study

  4. Has had previous ocular surgery within the past 12 weeks

  5. Intolerance to PROSE wear

  6. Inability to maintain stable fixation and exposure for ocular surface imaging

  7. Corneal touch by the posterior surface of the device in current PROSE device

  8. Allergy to sodium fluorescein

  9. Patient is an employee of BostonSight

  10. Subject is currently incarcerated. -

Contacts and Locations

Locations

Site City State Country Postal Code
1 BostonSight Needham Massachusetts United States 02494

Sponsors and Collaborators

  • Boston Sight
  • EYEdeal scanning, LTC

Investigators

  • Principal Investigator: Daniel Brocks, MD, Boston Sight

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Daniel C Brocks, Chief Medical Officer, Boston Sight
ClinicalTrials.gov Identifier:
NCT04649177
Other Study ID Numbers:
  • BFS-OCT-01
First Posted:
Dec 2, 2020
Last Update Posted:
Mar 28, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 28, 2022